SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Miceli-Richard C, Dougados M. NSAIDs in ankylosing spondylitis. Clin Exp Rheumatol 2002; 20 Suppl 28: S656.
  • 2
    Braun J, Sieper J. Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNFα therapy and other novel approaches. Arthritis Res 2002; 4: 30721.
  • 3
    Van der Horst-Bruinsma IE, Clegg DO, Dijkmans BA. Treatment of ankylosing spondylitis with disease-modifying antirheumatic drugs. Clin Exp Rheumatol 2002; 20 Suppl 28: S6770.
  • 4
    Braun J, Bollow M, Neure L, Seipelt E, Seyrekbasan F, Herbst H, et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 1995; 38: 499505.
  • 5
    Braun J, Sieper J. Anti-TNFα: a new dimension in the pharmacotherapy of the spondyloarthropathies!? Ann Rheum Dis 2000; 59: 4047.
  • 6
    Gorman JD, Sack KE, Davis JC. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor α. N Engl J Med 2002; 346: 134956.
  • 7
    Davis JC Jr, van der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, et al, for the Enbrel Ankylosing Spondylitis Study Group. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003; 48: 32306.
  • 8
    Van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, et al, and the Ankylosing Spondylitis Study for Evaluation of Recombinant Infliximab Therapy Study Group. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005; 52: 58291.
  • 9
    Van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J, et al, for the ATLAS Study Group. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006; 54: 213646.
  • 10
    Braun J, Landewe R, Hermann KG, Han J, Yan S, Williamson P, et al, for the ASSERT Study Group. Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study. Arthritis Rheum 2006; 54: 164652.
  • 11
    Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 1984; 27: 3618.
  • 12
    Anderson JJ, Baron G, van der Heijde D, Felson DT, Dougados M. Ankylosing Spondylitis Assessment Group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001; 44: 187686.
  • 13
    Brandt J, Listing J, Sieper J, Rudwaleit M, van der Heijde D, Braun J. Development and preselection of criteria for short term improvement after anti-TNFα treatment in ankylosing spondylitis. Ann Rheum Dis 2004; 63: 143844.
  • 14
    Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994; 21: 228691.
  • 15
    Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994; 21: 22815.
  • 16
    Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL, Calin A. Defining spinal mobility in ankylosing spondylitis (AS): the Bath AS Metrology Index. J Rheumatol 1994; 21: 16948.
  • 17
    Scott DL, van Riel PL, van der Heijde D, Benke AS. Assessing disease activity in rheumatoid arthritis. In: The EULAR handbook of standard methods. 2nd ed. Uppsala (Sweden): Pharmacia Graphic Communications; 1995. p. 20.
  • 18
    Mander M, Simpson JM, McLellan A, Walker D, Goodacre JA, Dick WC. Studies with an enthesis index as a method of clinical assessment in ankylosing spondylitis. Ann Rheum Dis 1987; 46: 197202.
  • 19
    Ware JE, Kosinski M, Keller SD. SF-36 physical and mental health summary scales: a user's manual. Boston: The Health Institute; 1994.
  • 20
    Wagner CL, Schantz A, Barnathan E, Olson A, Mascelli MA, Ford J, et al. Consequences of immunogenicity to the therapeutic monoclonal antibodies ReoPro and Remicade. Dev Biol (Basel) 2003; 112: 3753.
  • 21
    Zink A, Braun J, Listing J, Wollenhaupt J, and the German Collaborative Arthritis Centers. Disability and handicap in rheumatoid arthritis and ankylosing spondylitis? Results from the German Rheumatologic Database. J Rheumatol 2000; 27: 61322.
  • 22
    Gran JT, Skomsvoll JF. The outcome of ankylosing spondylitis: a study of 100 patients. Br J Rheumatol 1997; 36: 76671.
  • 23
    Boonen A. Socioeconomic consequences of ankylosing spondylitis. Clin Exp Rheumatol 2002; 20 Suppl 28: S236.
  • 24
    Braun J, Brandt J, Listing J, Zink A, Alten R, Burmester G, et al. Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial. Arthritis Rheum 2003; 48: 222433.
  • 25
    Braun J, Brandt J, Listing J, Zink A, Alten R, Burmester G, et al. Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Ann Rheum Dis 2005; 64: 22934.
  • 26
    Braun J, Baraliakos X, Brandt J, Listing J, Zink A, Alten R, et al. Persistent clinical response to the anti-TNFα antibody infliximab in patients with ankylosing spondylitis over 3 years. Rheumatology (Oxford) 2005; 44: 6706.
  • 27
    De Vries MK, Wolbink GJ, Stapel SO, de Groot ER, Dijkmans BA, Aarden LA, et al. Inefficacy of infliximab in ankylosing spondylitis is correlated with antibody formation. Ann Rheum Dis 2007; 66: 1334.
  • 28
    REMICADE (infliximab) for IV injection prescribing information. Malvern (PA): Centocor; 2006.
  • 29
    Breban M, Ravaud P, Claudepierre P, Baron G, Hudry C, Euller-Ziegler L, et al. No superiority of infliximab (INF) + methotrexate (MTX) over INF alone in the treatment of ankylosing spondylitis (AS): results of a one-year randomized prospective study [abstract]. Arthritis Rheum 2005; 52 Suppl 9: S2145.
  • 30
    Marzo-Ortega H, McGonagle D, Jarrett S, Haugeberg G, Hensor E, O'Connor P, et al. Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study. Ann Rheum Dis 2005; 64: 156875.